MRD monitoring before and after allo-HSCT predicts outcomes - AML Hub
Measurable residual disease (MRD) post-induction chemotherapy predicts relapse and shorter survival in AML patients, aiding in risk stratification and treatment response assessment. Recent studies at the ASH Meeting highlighted MRD's role in predicting relapse post-allo-HSCT. The Spanish AML12 trial demonstrated risk-adapted treatment feasibility based on AML genetics and MRD presence, involving 812 adults across 15 hospitals.
Reference News
Measurable residual disease (MRD) post-induction chemotherapy predicts relapse and shorter survival in AML patients, aiding in risk stratification and treatment response assessment. Recent studies at the ASH Meeting highlighted MRD's role in predicting relapse post-allo-HSCT. The Spanish AML12 trial demonstrated risk-adapted treatment feasibility based on AML genetics and MRD presence, involving 812 adults across 15 hospitals.